{"nctId":"NCT02162667","briefTitle":"Efficacy and Safety Evaluating Study of CT-P6 in Her2 Positive Early Breast Cancer","startDateStruct":{"date":"2014-06","type":"ACTUAL"},"conditions":["HER2-positive Carcinoma of Breast"],"count":562,"armGroups":[{"label":"CT-P6","type":"EXPERIMENTAL","interventionNames":["Drug: Trastuzumab"]},{"label":"Trastuzumab","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Trastuzumab"]}],"interventions":[{"name":"Trastuzumab","otherNames":["Herceptin"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patient who has histologically confirmed and newly diagnosed breast cancer\n* Patient who has clinical stage I, II, or IIIa operable breast cancer according to AJCC (American Joint Committee on Cancer) Breast Cancer Staging 7th edition\n* Patient who has HER2-positive status confirmed locally, defined as 3+ score by IHC (immuno-histochemistry).\n\nExclusion Criteria:\n\n* Patient who has bilateral breast cancer\n* Patient who has received prior treatment for breast cancer, including chemotherapy, biologic therapy, hormone therapy, immunotherapy, radiation or surgery, including any prior therapy with anthracyclines.","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"The Percentage of Patients Achieving Pathological Complete Response Defined as the Absence of Invasion Tumor Cells in the Breast and in Axillary Lymph Nodes, Regardless of Ductal Carcinoma in Situ (DCIS)","description":"Subject who went through Neoadjuvant period completely (24 weeks), will receive surgery within 3-6 weeks after last treatment of neoadjuvant period.\n\nThe primary endpoint, Pathological complete response, will be assessed using resected bio-specimens collected in breast and axilla during a surgery.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"46.77","spread":null},{"groupId":"OG001","value":"50.39","spread":null}]}]}]},{"type":"SECONDARY","title":"The Percentage of Patients Achieving Pathological Complete Response (pCR) of the Breast Regardless of DCIS With Positive or Unknown Nodal Status","description":"Subject who went through Neoadjuvant period completely (24 weeks), will receive surgery within 3-6 weeks after last treatment of neoadjuvant period.\n\nThe secondary endpoint, other than pCR of breast and axillary nodes ragardless of DCIS which was primary endpoint, will be assessed using resected bio-specimens collected in breast and axilla during a surgery.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.84","spread":null},{"groupId":"OG001","value":"4.69","spread":null}]}]}]},{"type":"SECONDARY","title":"The Percentage of Patients Achieving Pathological Complete Response of the Breast and Axillary Nodes With Absence of DCIS","description":"Subject who went through Neoadjuvant period completely (24 weeks), will receive surgery within 3-6 weeks after last treatment of neoadjuvant period.\n\nThe secondary endpoint, other than pCR of breast and axillary nodes ragardless of DCIS which was primary endpoint, will be assessed using resected bio-specimens collected in breast and axilla during a surgery.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"39.92","spread":null},{"groupId":"OG001","value":"41.41","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Response Rate (ORR) From Local Review","description":"The ORR was defined as the proportion of patients with a BOR of CR or PR as assessed by RECIST guideline Version 1.1 during the Nedadjuvant Period.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"84.27","spread":null},{"groupId":"OG001","value":"83.98","spread":null}]}]}]},{"type":"SECONDARY","title":"Disease-free Survival","description":"Patients who underwent breast surgery were included in the DFS analysis. Disease-free survival was defined as the interval between the date of breast surgery and disease progression, recurrence, or death from any cause, whichever occurred first. Only a recurrence or progression of disease that occurred before beginning another anticancer therapy was regarded as an event.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.95","spread":null},{"groupId":"OG001","value":"0.96","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.87","spread":null},{"groupId":"OG001","value":"0.89","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.82","spread":null},{"groupId":"OG001","value":"0.82","spread":null}]}]}]},{"type":"SECONDARY","title":"Progression-Free Survival","description":"Progression-free survival was defined as the interval between randomization and disease progression, recurrence, or death from any cause, whichever occurred first. Only a recurrence or progression of disease that occurred before beginning another anticancer therapy was regarded as an event.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.99","spread":null},{"groupId":"OG001","value":"0.98","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.90","spread":null},{"groupId":"OG001","value":"0.93","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.82","spread":null},{"groupId":"OG001","value":"0.87","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival","description":"Overall survival was defined as the interval between randomization and death from any cause.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.00","spread":null},{"groupId":"OG001","value":"1.00","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.98","spread":null},{"groupId":"OG001","value":"0.98","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.95","spread":null},{"groupId":"OG001","value":"0.94","spread":null}]}]}]},{"type":"SECONDARY","title":"The Number of Patients Who Had Progressive Disease or Recurrence","description":"If recurrence or progression of disease occurred at any time during the study, the progressed tumor site was recorded in the \"recurrence or progression of disease\" eCRF page as local, regional, or distant, with diagnostic method and whether positive cytology or histology or not.\n\nThe resulting recurrence or progression of disease information was summarized as secondary endpoint.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"41","spread":null},{"groupId":"OG001","value":"35","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35","spread":null},{"groupId":"OG001","value":"30","spread":null}]}]}]},{"type":"SECONDARY","title":"Maximum Serum Concentration After Administration (Cmax) in Each Cycle","description":"Pharmacokinetic samples were collected before study drug (CT-P6 or US-licensed Herceptin) administration (within 15 minutes prior to the beginning of the study drug infusion) and within 15 minutes after the end of the study drug infusion for each cycle during the Neoadjuvant Period. After the completion of treatment, an additional PK sample was collected at the EOT1.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"186.428","spread":"69.0828"},{"groupId":"OG001","value":"178.567","spread":"55.3800"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"145.078","spread":"47.7899"},{"groupId":"OG001","value":"138.989","spread":"45.7103"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"145.183","spread":"44.5392"},{"groupId":"OG001","value":"141.130","spread":"43.8189"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"148.541","spread":"54.2737"},{"groupId":"OG001","value":"137.465","spread":"45.6914"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"136.210","spread":"44.6078"},{"groupId":"OG001","value":"135.307","spread":"47.1950"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"143.569","spread":"42.4510"},{"groupId":"OG001","value":"143.605","spread":"51.2868"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"146.726","spread":"48.0249"},{"groupId":"OG001","value":"141.468","spread":"43.1823"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"145.081","spread":"41.5382"},{"groupId":"OG001","value":"144.238","spread":"57.3618"}]}]}]},{"type":"SECONDARY","title":"Trough Serum Concentration (Ctrough) in Each Cycle","description":"Pharmacokinetic samples were collected before study drug (CT-P6 or US-licensed Herceptin) administration (within 15 minutes prior to the beginning of the study drug infusion) and within 15 minutes after the end of the study drug infusion for each cycle during the Neoadjuvant Period. After the completion of treatment, an additional PK sample was collected at the EOT1.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18.915","spread":"22.9964"},{"groupId":"OG001","value":"18.905","spread":"21.2967"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.346","spread":"17.9771"},{"groupId":"OG001","value":"16.773","spread":"16.8134"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.796","spread":"17.2409"},{"groupId":"OG001","value":"17.816","spread":"23.3438"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.851","spread":"20.1572"},{"groupId":"OG001","value":"15.904","spread":"15.8754"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.403","spread":"19.9042"},{"groupId":"OG001","value":"17.962","spread":"17.9429"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.902","spread":"20.2198"},{"groupId":"OG001","value":"18.256","spread":"17.6964"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.540","spread":"14.3313"},{"groupId":"OG001","value":"18.718","spread":"18.5976"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.901","spread":"7.2203"},{"groupId":"OG001","value":"17.129","spread":"10.0491"}]}]}]},{"type":"POST_HOC","title":"The Percentage of Patients Achieving Pathological Complete Response of the Breast and Axillary Nodes Regardless of DCIS","description":"Subject who went through Neoadjuvant period completely (24 weeks), will receive surgery within 3-6 weeks after last treatment of neoadjuvant period.\n\nThe secondary endpoint, other than pCR of breast and axillary nodes ragardless of DCIS which was primary endpoint, will be assessed using resected bio-specimens collected in breast and axilla during a surgery.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"51.61","spread":null},{"groupId":"OG001","value":"55.08","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":22,"n":271},"commonTop":["Alopecia","Neutropenia","Nausea","Anaemia","Fatigue"]}}}